Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Creatine Monohydrate for Mild Traumatic Brain Injury: a Randomised Controlled Pilot Study

A legfontosabb adatok

Ki végzi
University of Southern Denmark
Hol
Dánia1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Résztvevők
34 fő vett részt
Kezdés
2023. aug. 1.
Befejezés
2024. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Creatine Monohydrate
  • Sugar Pill (Placebo)
A regiszteradat frissítve
2026. április 7.

Ki vehet részt

Életkor
20 év – 45 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 5 feltétel megnézéseKevesebb

Ki vehet részt

  • The time since concussion was 6-18 months
  • The age range was 20-45 years
  • Only participants who had not initiated any new pharmacological or non-pharmacological treatments from three weeks prior to inclusion until study completion were eligible

Ki nem vehet részt

  • Moderat to high level of intensity for no more than 10 hours per week
  • Pregnant

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Objectives: Approximately one-third of patients with concussion experience persistent symptoms that, in addition to causing serious discomfort, may lead to unemployment and other socioeconomic challenges. Animal studies suggest that creatine monohydrate may alleviate post-concussive symptoms. This pilot study investigated the effects of creatine monohydrate on post-concussive symptoms in humans and assessed the feasibility of the pilot trial.

A teljes eredeti leírásKevesebb

Design: Three-arm randomised controlled pilot trial (intervention, placebo, control).

Setting: Participants were recruited through neurological outpatient clinics and public outreach in Denmark.

Participants: The study included 34 participants aged 20-45 years who had been experiencing persistent post-concussive symptoms for 6-18 months since injury. Participants were randomised to one of three groups.

Intervention: The intervention group received 5 g of creatine monohydrate daily for seven weeks. The placebo group received an identical inert powder following the same regimen. The control group received usual care only.

Primary and secondary outcome measures: The primary outcome was post-concussion symptoms (Rivermead Post Concussion Symptoms Questionnaire (RPQ)). Secondary outcomes were acute (RPQ-3) and persistent (RPQ-13) symptoms, assessed at three time points (week 0, 4 and 8).

Results: All participants completed follow-up, indicating the trial's high feasibility and practicality. The intervention group did not significantly differ from the placebo or control groups. Moderate effect sizes were noted for RPQ-13 and total RPQ scores (d = -0.47, -0.46) and small for RPQ-3 scores (d = -0.22), although none reached statistical significance. Similar effects were observed between the placebo and control groups.

Conclusions: The study showed strong usability and practical feasibility. Effect sizes were exploratory and not indicative as evidence of treatment efficacy at this stage. Larger randomized controlled trials are needed to determine whether creatine monohydrate could be a safe, accessible adjunctive treatment for post-concussive symptoms.

A vizsgálat 3 csoportja

  • Intervention group (Creatine)A vizsgált kezelés

    Creatine Monohydrate administered once a day for seven weeks - with 5 g/day for the entire period.

    Kezelés: Creatine Monohydrate

  • Control group - No treatmentNincs vizsgálati kezelés, összehasonlításként

    The control group will receive standard care. However, to our knowledge there is no common accepted description of standard care in the literature. In general, these participants will be advised to keep as asymptomatic as possible throughout seven weeks, and live as normal as possible.

  • Placebo group (Sugar pill)Placebo, összehasonlításként

    Powdered sugar administered once a day for seven weeks - with 5 gram/day for the entire period.

    Kezelés: Sugar Pill (Placebo)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. április 7.